Win-Win For Alnylam And Dicerna With RNAi Trade Secrets Settlement
Executive Summary
Although Dicerna needs to make some payments to Alnylam to settle a patent infringement case, the company has avoided an expensive court trial and is free to find partners for its early-stage RNAi therapeutics programs.